Stifel上调Edwards Lifesciences股票评级至买入，目标价提高至$90
周四，Stifel分析师将Edwards Lifesciences股票评级从持有上调至买入，理由是经导管主动脉瓣置换（TAVR）市场的潜在增长加速。该公司还将Edwards Lifesciences的目标价从$75.00上调至$90.00。根据 InvestingPro 数据，Edwards Lifesciences目前市值为$41.95 ...